Featured Research Search Results

Treating Advanced Endometrial or Ovarian Cancer with Targeted Therapies (ComboMATCH)

Clinicaltrials.gov identifier:
NCT05554328

Treatment
Phase 2 treatment study for recurrent endometrial or ovarian cancer

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

Clinicaltrials.gov identifier:
NCT05498272

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

Comparing an Investigational Targeted Drug AZD5335 to Standard Treatments in People With Platinum‑Resistant Ovarian Cancer (TREVI‑OC‑01)

Clinicaltrials.gov identifier:
NCT07218809

Treatment
Phase 3 treatment study for platinum-resistant ovarian cancer

Using a Blood Test to Detect Early Cancer Recurrence After Treatment (ORACLE)

Clinicaltrials.gov identifier:
NCT05059444

Treatment
Post-treatment study to monitor for recurrence

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Treating Advanced or Metastatic Breast Cancer with a Type of Immunotherapy Called CAR-T

Clinicaltrials.gov identifier:
NCT06878248

Treatment
Phase 1 treatment study for people with advanced solid tumors

Comparing an Experimental Drug Puxi-Sam with Standard Chemotherapy for Metastatic Endometrial Cancer (Bluestar‑Endometrial01)

Clinicaltrials.gov identifier:
NCT07044336

Treatment
Phase 3 treatment study for metastatic endometrial cancer

Testing a Combination of Immunotherapy and a Vaccine in People With Advanced Pancreatic or Lung Cancer

Clinicaltrials.gov identifier:
NCT06015724

Treatment
Phase 2 treatment study for advanced pancreatic and lung cancer

Treating Recurrent dMMR or MSI-High Endometrial Cancer with the Immunotherapy Drug, Nivolumab with or without the Immunotherapy Drug, Ipilimumab

Clinicaltrials.gov identifier:
NCT05112601

Treatment
Phase 2 treatment study for recurrent endometrial cancer with dMMR or MSI-High biomarker

Study of a New Drug, E7386, in Combination with Lenvatinib in People with Previously Treated Endometrial Cancer

Clinicaltrials.gov identifier:
NCT04008797

Treatment
Treatment study for people with previously treated endometrial cancer

Treating Advanced Breast or Other Solid Cancers Using a Combination of a New Targeted Therapy, ZEN003694, With The Targeted Therapy Abemaciclib (Verzenio)

Clinicaltrials.gov identifier:
NCT05372640

Treatment
Phase 1 treatment study for advanced breast cancer and other solid tumors

Study of a New Targeted Therapy Given Alone or in Combination with an Immunotherapy for Metastatic, Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT06841354

Treatment
Phase 3 treatment study for people with metastatic, triple-negative breast cancer

Treating Advanced Cancers with DNA-Repair Mutations Using MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib

Clinicaltrials.gov identifier:
NCT06545942

Treatment
Treatment study for people with advanced or metastatic cancers

Study of a New Investigational Inhibitor to Treat People with Advanced Solid Tumors

Clinicaltrials.gov identifier:
NCT05932862

Treatment
Treatment study for people with advanced solid tumors

Using a PARP Inhibitor and Oral Chemotherapy to Treat Advanced Solid Tumors with a Mutation in BRCA1, BRCA2, PALB2, ATM or CHEK2

Clinicaltrials.gov identifier:
NCT06177171

Treatment
Phase 1 treatment study for metastatic solid tumors

Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer

Clinicaltrials.gov identifier:
NCT07140679

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Maintenance Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer with a BRCA Mutation or a Biomarker Called HRD

Clinicaltrials.gov identifier:
NCT06580314

Treatment
Phase 3 ovarian cancer treatment study for people with BRCA mutation or HRD